These results for A were significantly HR , P ). Adjustment for follow-up systolic different than C, with all of the interaction P values . diastolic and K in Cox PH regression analyses with For those assigned to L, there was a significantly increased time-dependent covariat including fixed covariates exam-ined previous did not appreciably alter these HRs. In hypokalemi Osthole the adjusted HR for stroke slightly increased risk for hypokalemicspared with normokalemics at year for HF and CVD death . These results for L were significantly different than C, with all of the from to , for total deaths from to , and for interaction P values . CVD deaths from to . Similar in hyperkalemi the adjusted HR for stroke slightly increased from to , for total deaths from to , and for CVD deaths from to .
The interaction H likewi did not change appreciably. Overall mortality in hypokalemicspared with normokalemics wasposed of an 8 higher risk of CVD death and a 3 higher risk of non-CVD STI-571 clinical trial death . Mortality from CHD causes Daptomycin structure accounted for 4 of the CVD deaths but did not differ Development of hyperkalemia was far less frequent than hypokalemia and was moremon among L participants than C or A . In L participan those developing hyperkalemia were at in-creased risk of death -pared with normokalemics . Overal hyperkalemics were at significantly increased risk of-bined CVDpared with normokalemic but there were no significant interactions with treatment. Potassium supplementation was availabl and significantly between hypokalemic and normokalemic 6 of participants with K mmol/L at their first groups .
Notab mortality from cancer caus whichposed follow-up visit were re-ported to be on supplementation at the next visi. 8 of those with a K mmol/L and of Downloaded celestone solubility from hyper.ahajournals/ at New York University/ Medical Center New York on March 7, Alderman ALLHAT Serum Potassium and Cardiovascular Events Table . Cumulative No. of Even -Y Kaplan-Meier Event Rates per , Cox Proportional H Corresponding 5 C and P Values for Hyperkalemia and Normal Y Potassium Subgroups Within Drug Groups No. of Events -Y Rate per O Unadjust Adjust Drug Group A indicates amlodipine; C, chlorthalidone; CC bined cardiovascular disease; C coronary heart disease; C cardiovascular disease; heart failure; hazard ratio; L, lisinopril. Data show sample sizes for K and K , respectively: C an. A an. L and .
nadjusted Cox model gold for each oue included only terms for the K corresponding data for K are given in Table . group and the K groups relative to the normal potassium group. The ?The adjusted Cox model for each oue included main effects terms for hypokalemia/norm hyperkalemia/norm baseline characteristic: ag se rac type diabetes mellitu history CH history of other atherosclerotic CV cigarette smoke. baseline systolic blood pressure and serum potassium; and estimated glomerular filtration rate at y . Odds ratio was from a logistic model; proportional hazards assumption was violated. those with a K mmol/L were on supplementation. heterogeneity across treatment grou with HR in C signif-These percentages increased by year to 1 of those with icantly different from L. This large study with careful K mmol/L and 2 of those mmol/L. At year , ascertainment of clinical oues provides further assurance.